IceCure Medical (ICCM) Common Equity (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Common Equity data on file, last reported at $8.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $8.5 million, up 41.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (up 41.57% YoY), and the FY2025 annual result was $9.1 million, up 31.15% from the prior year.
• Common Equity declined to $8.5 million in Q1 2026 per ICCM's latest filing, from $9.1 million in the prior quarter.
• Over five years, Common Equity peaked at $25.4 million in Q4 2022 and troughed at $2.9 million in Q2 2025.
• A 5-year average of $13.2 million and a median of $11.6 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 72.75% in 2025, then surged 41.57% in 2026.
• A 5-year view of Common Equity shows it stood at $25.4 million in 2022, then plunged by 52.16% to $12.2 million in 2023, then sank by 43.26% to $6.9 million in 2024, then jumped by 31.15% to $9.1 million in 2025, then retreated by 6.15% to $8.5 million in 2026.
• Business Quant data shows ICCM's Common Equity at $8.5 million in Q1 2026, $9.1 million in Q4 2025, and $9.3 million in Q3 2025.